ArticleBMC gastroenterology2026
Analysis of the incidence and risk factors of colorectal polyps in patients with chronic hepatitis B complicated by non - alcoholic fatty liver disease.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the incidence of colorectal polyps in patients with chronic hepatitis B (CHB) complicated by non - alcoholic fatty liver disease (NAFLD) and its risk factors.
methodsA total of 505 patients who underwent electronic colonoscopy at The Tianjin Second People's Hospital from October 2018 to November 2023 and met the inclusion criteria were selected as the research subjects. They were divided into the CHB group, the NAFLD group, and the CHB + NAFLD group. Chi-square test, analysis of variance, and Kruskal Wallis rank sum test were used to compare the characteristics of the three groups of patients. Univariate and multivariate logistic regression were used to evaluate the risk factors for colorectal polyps in patients in the CHB + NAFLD group.
results(1) The detection rate of polyps in the NAFLD group was 73.9%, in the CHB + NAFLD group was 64.2%, and in the CHB group was 48.4%, with a statistically significant difference (P < 0.05). (2) There were statistically significant differences among the three groups in terms of sex, BMI, CAP, history of hypertension, ALT, GGT, ALB, FPG, TG, TC, TBA, UA, HDL, LDL, WBC, RBC, HGB, PLT, PT, and CA19-9(P < 0.05). (3) The CHB + NAFLD group mainly had multiple polyps (58.8%), most of the polyps were small, with polyps ≤ 0.5 cm accounting for 68.7%, and the proportion of polyps located in the distal colon was 40.5%. (4) In the comparison of inflammatory polyps among groups, detection rate of the NAFLD group was 9.8%, the CHB + NAFLD group was 5.3%, and the CHB group was 1.1%, with a statistically significant difference (P < 0.05).(5)Age(OR = 1.047,95%CI:1.016 ~ 1.080),diabetes(OR = 3.732,95%CI:1.044 ~ 13.335),WBC(OR = 1.272,95%CI:1.043 ~ 1.552) were independently associated with colorectal polyps development in the CHB + NAFLD group.
conclusionMore than half of the patients with CHB complicated by NAFLD can be detected with colorectal polyps. Age, diabetes, WBC were independently associated with colorectal polyps development in this group of people. Colonoscopy screening should be actively carried out for CHB patients complicated by NAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.